[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581340":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":38,"responsibleParty":54,"collaborators":26,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":26,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":26,"enrollmentInfo":68,"targetDuration":26,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Western Galilee Hospital-Nahariya","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Zinacef treatment","EXPERIMENTAL","women with meconium-stained amniotic fluid treated with zinacef 750 mg X3\u002Fd",[13],"Drug: zinacef tretment",{"label":15,"type":16,"description":17,"interventionNames":18},"control","PLACEBO_COMPARATOR","women with meconium-stained amniotic fluid treated with I.V SALINE 100 CCX3\u002Fd",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","zinacef tretment","prophylactic antibiotic treatment with zinacef",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"OTHER","Placebo","I.V SALINE 100 CC X3\u002Fd",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":26,"email":37},"Maya Frank Wolf, prof.","CONTACT","972-50-7887800","mayaw@gmc.gov.il",[39],{"facility":40,"status":41,"city":42,"state":26,"zip":26,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Galilee Medical center","RECRUITING","Nahariya","Israel","IL",{"type":46,"coordinates":47},"Point",[48,49],35.09814,33.00892,{"lat":49,"lon":48},[52],{"name":53,"role":35,"phone":36,"phoneExt":26,"email":37},"Maya Frank Wolf, Prof.",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Dr. Maya Wolf","Head of Maternal and Fetal medicine unit","100581340","comparing-infectious-morbidity-among-women-with-meconium-stained-amniotic-fluid-at-term-between-those-treated-with-prophylactic-antibiotics-zinacef-vs-placebo-100581340",false,"NCT06849037","Comparing Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Treated With Prophylactic Antibiotics Zinacef vs. Placebo","and Infectious Morbidity Among Women With Meconium-stained Amniotic Fluid at Term, Between Those Who Will be Treated With Prophylactic Antibiotics Zinacef vs. Placebo","Inclusion Criteria:\n\n* singleton pregnancy at term\n* meconium-stained amniotic fluid\n\nExclusion Criteria:\n\n* Intrauterine fetal death\n* GBS carriers\n* zinacef allergy\n* antibiotic treatment for other indication",true,"FEMALE","18 Years",{"count":69,"type":70},182,"ESTIMATED","INTERVENTIONAL",[73],"NA","Our randomized controlled double blind clinical trail aims to compare maternal and neonatal infectious morbidity between women with meconium-stained amniotic fluid treated with zinacef vs. placebo.",[76,77],"Meconium-stained Amniotic Fluid","Chorioamnionitis",[79,80,81,82,83],"meconium-stained amniotic fluid","antibiotic treatment","infectious morbidity","chorioamnionitis","zinacef","2025-07-16",{"date":86,"type":87},"2025-07-20","ACTUAL",{"date":89,"type":87},"2025-02-18",{"date":91,"type":70},"2029-02-13",{"name":5,"class":6},1]